CMP: 375


Biocon Ltd., is an integrated biotechnology enterprise with a presence in biopharmaceuticals, enzymes, custom research and clinical research. The Company's pharmaceutical products include statins, immunosuppressants and anti-diabetic drugs. Biocon also manufactures specialty enzymes and new enzyme applications besides providing clinical and custom research services.

Biocon is an excellent pick in mid-cap pharma space. Its currently trading at a P/E of 17. Decent dividend yields of close to 1% in the last 12 months. Minimal liabilities with varying NPM from 15% to 50% in the last 5 years. NPM currently strong at 25%. Revenues are growing strong at around 100% in FY11. Buy, Accumulate on dips of 10% and hold for long term gains.